The low and mid-dose groups (AML and AMM) decreased Bmp15 and Nobox mRNA expression (P < 0.01, Fig. 5F), while the high-dose group decreased Nobox without affecting Bmp15 mRNA expression (Fig. 5F). This evidence concerns the gene NOBOX and acute myeloid leukemia.